MSB 0.92% $1.08 mesoblast limited

Phase 3 DREAM HF-1 read-out, page-341

  1. 7,768 Posts.
    lightbulb Created with Sketch. 1337
    I would be very interested to know what the all cause mortality rate was in either groups.

    According to data I've seen, 3 year survival for NYHA class 2 patients is roughly 70-80%.

    As they measure at 30 months you would assume their survival in the control group would be towards the higher end of that range.

    Now with say, a 25% mortality rate in a subgroup of 103 patients (206 with an assumed 50/50 control), that would be say 27 people died in the control group.

    For a 60% reduction in mortality, that's roughly a difference of 10 people, right?

    For a mortality difference of 10 patients in cohorts of 103 per arm I don't see how they got a significance of <0.037.

    I haven't plugged it into an equation, but that seems like a very small difference in an N that isn't extremely large.

    I know there are some stats experts in here, I'd love to be corrected.
    Last edited by DocMcstuffins: 16/12/20
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.08
Change
-0.010(0.92%)
Mkt cap ! $1.233B
Open High Low Value Volume
$1.10 $1.11 $1.05 $5.002M 4.632M

Buyers (Bids)

No. Vol. Price($)
2 5697 $1.08
 

Sellers (Offers)

Price($) Vol. No.
$1.09 1000 1
View Market Depth
Last trade - 16.10pm 14/06/2024 (20 minute delay) ?
Last
$1.09
  Change
-0.010 ( 0.10 %)
Open High Low Volume
$1.09 $1.11 $1.06 1181223
Last updated 15.59pm 14/06/2024 ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.